MedTrace Logo

A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients

NCT01755897 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2023-05-09

No results posted yet for this study

Summary

We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical cancer patients with risk factors.

Conditions

Interventions

PROCEDURE

radical hysterectomy + pelvic lymph node dissection

DRUG

Paclitaxel

135-175 mg/m(2) intravenously (IV) on day 1

DRUG

Cisplatin

75 mg/m(2) IV on day 2 and 3

DRUG

Cisplatin

35 mg/m(2) IV once a week

RADIATION

Pelvic RT

IMRT

Sponsors & Collaborators

  • Zhejiang University

    collaborator OTHER

  • Shandong University

    collaborator OTHER

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Ding Ma, MD, PhD · Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755897 on ClinicalTrials.gov